Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Synthetic small-molecule complement inhibitors.

M Claire H Holland1, Dimitrios Morikis, John D Lambris

  • 1University of Pennsylvania, Protein Chemistry Laboratory, Department of Pathology and Laboratory Medicine, 402 Stellar Chance, 422 Curie Blvd, Philadelphia, PA 19104, USA.

Current Opinion in Investigational Drugs (London, England : 2000)
|December 3, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

New Analogs of the Compstatin Family of Clinical Complement Inhibitors with Low Picomolar Target Affinity.

Journal of medicinal chemistry·2026
Same author

Clinical C3 Inhibition With AMY-101 Reveals Novel Insights Into IL-8-Driven Inflammation in COVID-19.

Immunology·2025
Same author

'Complement-ing' tissue inflammation via granzyme K?

Nature immunology·2025
Same author

Cp40-mediated complement C3 inhibition dampens inflammasome activation and inflammatory mediators storm induced by Bitis arietans venom.

International immunopharmacology·2025
Same author

The C5a/C5aR1 Axis Promotes Migration of Tolerogenic Dendritic Cells to Lymph Nodes, Impairing the Anticancer Immune Response.

Cancer immunology research·2024
Same author

Monocyte uptake of polymeric peptidoglycan is bimodal and governed by complement C3 and C4 opsonins.

JCI insight·2024
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

Small molecule inhibitors targeting the complement system, including compstatin, 3D53, and SB-290157, show promise for treating inflammatory diseases with good efficacy and low toxicity.

Area of Science:

  • Immunology
  • Pharmacology

Background:

  • Large molecular-weight complement inhibitors are in clinical trials for inflammatory conditions.
  • Small synthetic complement inhibitors offer advantages and are rapidly developing.

Purpose of the Study:

  • To review three small molecule complement inhibitors: compstatin, 3D53, and SB-290157.
  • To discuss their potential for therapeutic development in inflammatory diseases.

Main Methods:

  • Review of compstatin, a C3-binding peptide.
  • Analysis of 3D53, a synthetic peptidic C5a receptor antagonist.
  • Examination of SB-290157, a non-peptidergic C3a receptor antagonist.

Main Results:

  • Compstatin analogs show increased activity and stability.

Related Experiment Videos

  • 3D53 and SB-290157 demonstrated efficacy in animal models of inflammatory diseases.
  • These small molecules exhibit minimal toxicity.

    • Conclusions:

    • Optimized compstatin analogs are promising.
    • 3D53 and SB-290157 are effective and safe for further therapeutic development.
    • Small molecule complement inhibitors represent a promising avenue for treating inflammatory conditions.